# New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Canonical URL: https://biopharmsignal.com/news/ROIV/new-england-journal-of-medicine-publishes-positive-phase-3-valor-trial-results-of-brepocitinib-in-dermatomyositis
Ticker: ROIV
Company: Roivant
Source: Roivant
Published: 2026-03-28 19:00 EST
Original Source URL: https://investor.roivant.com
## Summary

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with

## Article Body
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with
## Recent Company News
- 2026-05-20 11:00 EST — [Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update](https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provides-business-update) — Source: Roivant
- 2026-05-11 20:05 EST — [Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/ROIV/roivant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Roivant
- 2026-04-02 09:00 EST — [Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)](https://biopharmsignal.com/news/ROIV/priovant-expands-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp) — Source: Roivant
- 2026-04-02 09:00 EST — [Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)](https://biopharmsignal.com/news/ROIV/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted) — Source: Roivant
- 2026-03-28 19:00 EST — [New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis](https://biopharmsignal.com/news/ROIV/new-england-journal-of-medicine-publishes-positive-phase-3-valor-trial-results-of-brepocitinib-in-dermatomyositis) — Source: Roivant
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)